Long-term safety survey of AJOVY injection for migraine in routine use
Observes long-term safety of fremanezumab injection in adults with migraine.
Plain-language title generated from the registry record
Registry title: Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
Key facts
- Where
- Osaka, JapanSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with migraine who use AJOVY (fremanezumab) injections, to follow long-term safety in real-life use.
- Age
- 18 years and older
- Sex
- All sexes can join.
Main reasons for not taking part
- Known hypersensitivity (allergy) to components of AJOVY
Read by machine on 9 November 2026.
Where in Japan
- Pharmacovigilance DepartmentOsaka, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Otsuka Pharmaceutical Co., Ltd.
- Trial code
- NCT05342493
- Record updated
- 22 June 2026
- Original description
To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.Read full original descriptionShow less
AJOVY Subcutaneous Injection Long-term Specified Use-results Survey
To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.
Inclusion: -.
Exclusion: patients with a known hypersensitivity to components of AJOVY.